Skip to main content

Table 4 Summary of Pharmacokinetic Parameters of Metformin

From: Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin

Treatment Day- 1 Metformin alone Day 13 Metformin + RE
AUC
(0-tau)
(hr.ng/mL)
Cmax
(ng/mL)
tmax
(hr)
AUC
(0-tau)
(hr.ng/mL)
Cmax
(ng/mL)
tmax
(hr)
Metformin + 12,305 1967 2.0 13,955 2041 2.5
Placebo (20) (22) (0.5–4.0) (24) (24) (0.75–8.0)
Metformin + 13,895 2162 3.0 14,693 2166 2.5
RE 500 mg (24) (24) (0.5–4.0) (25) (28) (0.75–4.0)
Metformin + 11,319 1758 2.5 11,392 1695 2.0
RE 750 mg + (33) (26) (0.5–4.0) (37) (34) (0.5–4.1)
  1. RE Remogliflozin Etabonate
  2. Values are geometric mean (%CVb) for each parameter, except for tmax which are median (range)